University of Zaragoza

The novel vaccine candidate against tuberculosis, MTBVAC, initiates Phase 1B clinical trial

By Biofabri, University of Zaragoza, SATVI, TBVI
Published: Sept. 20, 2015, 8:04 p.m.· Tags: Vaccines, Scientific research

The clinical trial will be conducted by South African Tuberculosis Vaccine Initiative (SATVI).
Biofabri, biotechnology company focusing on human health vaccines, will sponsor the Phase 1B clinical trial.

Read More →

Page 1 of 1 · Total posts: 1

1